SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT05020769, led by Sichuan Baili Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer. Planned enrolment is 14 participants (actual). The study started in 2022-01-06 and primary completion is expected in 2025-12. No results have been posted on ClinicalTrials.gov.